Xlife Sciences AG explores listing on SIX Swiss Exchange

Xlife Sciences AG / Key word(s): Regulatory Admission
Xlife Sciences AG explores listing on SIX Swiss Exchange

18-Nov-2021 / 20:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP Ad-hoc-Service

November 18, 8 pm CET

Media release

Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange

Xlife Sciences, a Swiss company developing new technologies and treatments in the life sciences sector and currently admitted to trading on the Munich Stock Exchange, today announced that it is exploring the possibility of a listing on SIX Swiss Exchange in Q1 2022, subject to market conditions. The intention with such a potential listing and move to a regulated market is to make the company more accessible to institutional investors, increase liquidity in the share, and further enhance the awareness and transparency of Xlife Sciences.

In the case, a listing on SIX Swiss Exchange is completed, the trading of the shares of Xlife Sciences on the Munich Stock Exchange would need to be discontinued for regulatory reasons before the start of trading on SIX Swiss Exchange. The tradability for existing shareholders will be ensured in the case of a move to SIX Swiss Exchange. The company will provide a further update once a formal decision has been taken.

About Xlife Sciences

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life
science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

Contact

For media inquiries: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

For investor inquiries: Dennis Lennartz, Head Investor Relations, Xlife Sciences AG, Phone +41 44 385 84 60, dennis.lennartz@xlifesciences.ch

18-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de